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ABSTRACT
Motor vehicle accidents (MVA) are one of the leading causes of 
death and injury in Turkey. Fatality reduction currently targets 
increasing seat belt use and reducing high-speeding and alcohol 
usage.  However, sleepiness is increasingly recognized as a 
contributing factor. Sleepiness accounts for up to 20% of MVAs 
on monotonous roads, especially highways. The most common 
medical disorder causing sleepiness is obstructive sleep apnea 
(OSA). Available data suggest that efficient treatment of OSA 
may reduce MVAs and MVA-related deaths and injuries. Several 
attempts have intensively been debated during the last decade in 
order to develop national and international strategies to screen 
high-risk drivers for sleepiness and OSA. In accordance with 
the directive of the European Union, the Turkish legislation has 
recently been revised for regulation of driving license issues for 
individuals with OSA. There are still many controversies and 
difficulties in implementation of these rules in practice. A full-
night polysomnography (PSG) is recommended, and treatment 
should be initiated as soon as possible when the OSA diagnosis is 
confirmed. However, given the limited resources, at-home portable 
cardiorespiratory sleep monitoring is a reasonable alternative to 
PSG for appropriately selected patients with high clinical suspicion 
for OSA, rather than no-PSG, and no treatment. Additional attempts 
for development of national guidelines for determining the driving 
risk, development of new screening tools for objective evaluation 
of sleepiness in drivers with suspected or confirmed OSA, and 
educating patients about the risks of excessive sleepiness as well 
as encouraging clinicians to become familiar with relevant laws 
are urging.
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Introduction
Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a chronic disease 
characterized by repeated upper-airway collapse during 
sleep, resulting in intermittent hypoxia, fragmented sleep, 
fluctuations in blood pressure, and increased sympathetic 
nervous system activity [1].  Population studies in the USA 
in the early 1990s suggested that the prevalence of OSA 
- defined by an apnea-hypopnea index (AHI) greater than 
five events per h was estimated to be 9% in women, and 
24% in men, respectively [2]. A later study from the USA 
showed an increased prevalence, corresponding around 17% 
in middle-aged (30-70 years) women, and 34% in middle-
aged men, which was mainly attributed to increasing body-
mass-index in general populations over the last decades [3]. 
Interestingly, a recent study in Europe, the HypnoLaus Study, 
based on recent apnea-hypopnea definitions of the American 
Academy of Sleep Medicine [4] revealed that 84% of men 
and 61% of women had OSA based on the polysomnographic 
AHI cut-off level of 5/h in an unselected general cohort of 
1525 adults [5].  The authors concluded that the prevalence 
of OSA was highly dependent on technical procedures such 
as using nasal cannulas recording more subtle breathing 
variations as hypopneas (instead of thermistors which were 
used earlier, and which are known to have less sensitivity) as 
well as applying the latest hypopnea definitions, which are 
more liberal compared to the earlier ones (3% desaturations 
instead of 4% desaturations, and/or arousals). To date, there 
is no data regarding the prevalence of OSA in Turkey based 
on sleep recordings. However, the largest questionnaire-
based Turkish Adult Population Epidemiology of Sleep 
(TAPES) study [6] including a nationwide representative 
sample of 5021 participants suggested a prevalence of OSA 
around 14% based on the Berlin questionnaire [7]. 
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Motor vehicle accidents in Turkey
According to a recent report, the total number of motor vehicle 
accidents (MVA) is continuously increasing in Turkey; there 
were 1,296,634 registered accidents in 2012 compared to 
439,777 accidents in 2002 [8]. The percentage of accidents 
per registered motor vehicles was also increased from 5.1% 
in 2002 to 7.6% in 2012. The deaths per general population 
was almost same (0.006% vs. 0.005%); however, the serious 
injuries per general population have been increased from 
0.168% to 0.354%; corresponding a total number of 3,750 
deaths and 268,079 serious injuries in 2012 [8]. According 
to the accident statistics, the drivers have the biggest defect 
share with a 95% ratio, and the main components of the 
driver defects were high speed, alcohol and substance use as 
well as sleepiness and fatigue [8]. 
Sleepiness and fatigue
Excessive daytime sleepiness (EDS) at the wheel has been 
identified as an important risk factor for MVA, and the 
excess risk of MVA due to sleepiness and fatigue has been 
estimated at 10-20% [9, 10]. The prevalence of the EDS in 
Turkey was estimated to be 5.4% in the TAPES study [6]. 
OSA is an important contributor to the occurrence of EDS in 
general population [11, 12], and the condition is associated 
with a two-to sevenfold increased risk for MVA [11, 13, 14]. 
Crashes due to EDS typically involve running off the road or 
into the back of another vehicle [15]. 
Other causes of EDS are insufficient sleep, which is 
associated with prolonged wakefulness or chronic sleep 
restriction due to long hours of work or play [16,17], shift 
work (comprising 7.4% of all those employed), or a variety 
of medical and neurological disorders [9,18,19].
Epworth Sleepiness Scale (ESS) is the most commonly 
used tool for subjective sleepiness [20], assessed by eight 
questions. The total ESS score ranges from 0 to 24; scores 
below 7 were considered as normal, 8–10 as moderate 
sleepiness, ≥11–15 was applied to define an elevated risk, 
whereas ≥16, severe EDS, was considered as high risk 
of falling asleep in various monotonous situations [11]. 
Treatment of OSA with continuous positive airway pressure 
(CPAP) eliminates apneas, reduces daytime symptoms [21], 
which may reduce the excess MVA risk [12, 22]. 
Prediction of MVA risk in the European Sleep Apnea 
Database cohort
The European Sleep Apnea Database (ESADA), started in 
2007, is an ongoing clinical and prospective cohort study 
comprising patients with suspected OSA referred to 25 
clinical sleep centers, 21 of them affiliated to universities, 
in 18 countries [23]. In this cohort, approximately 82% 
(n = 6984 of 8476)were license holders [24]. Of the four 
previously validated risk factors for MVA history (ESS 
score≥16; habitual sleep time ≤5 h; use of hypnotics; annual 
driving distance ≥15 000 km), at least one was identified 
in more than half of the cohort [24]. Predictors associated 
with severe EDS in a multivariate analysis were age, female 
gender, BMI, AHI and long driving distance. Importantly, 
OSA severity was associated weakly with MVA risk factors, 
and in another validation study from Gothenburg, Sweden, 
AHI alone did not provide a valid diagnostic marker for 
MVA risk [22]. 
New standards and guidelines for drivers with OSA
The increasing awareness about OSA as a risk factor 
for MVAs, which is reversed by efficient treatment with 
CPAP, has led to a revision of annex III of the European 
Union (EU) directive on driving licenses that is subject 
to mandatory implementation by all member states from 
December 31, 2015 [25]. This directive was based on the 
recommendations from a working group established by 
the Transport and Mobility Directorate of the European 
Commission in 2012 [26]. As summarized briefly in a recent 
editorial [27], this directive includes: a) Applicants or drivers 
in whom a moderate or severe OSA syndrome is suspected 
shall be referred for further authorized medical advice 
before a driving license is issued or renewed. They may 
be advised not to drive until confirmation of the diagnosis; 
b) Driving licenses may be issued to applicants or drivers 
with moderate or severe OSA syndrome who show adequate 
control of their condition and compliance with appropriate 
treatment and improvement of sleepiness, if any, confirmed 
by authorized medical opinion; c) Applicants or drivers 
with moderate or severe OSA syndrome under treatment 
shall be subject to a periodic medical review, at intervals 
not exceeding 3 years for noncommercial drivers, and 1 year 
for commercial drivers, with a view to establish the level of 
compliance with the treatment, the need for continuing the 
treatment and continued good vigilance. 
Turkish legislation by 26.09.2006
The first legislation regarding OSA and driving license in 
Turkey was published on September 26, 2006 [28] stating 
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that: a) all driving license applicants with symptoms 
regarding snoring, witnessed apneas and/or daytime 
sleepiness; and all commercial driver-license applicants 
older than 45 years, and those with BMI >25 kg/m2 should 
undergo polysomnography (PSG) before getting a license 
(and these reports should be renewed every year); b) The 
ones with AHI >15/h should be treated surgically or by 
CPAP or Bilevel Positive Airway Pressure (BiPAP), and 
the efficient treatment should be documented on PSG every 
year [28]. 
Unfortunately, this legislation has not been in practical 
use because the number of applicants is substantially greater 
than the capacity of the sleep centers to test them, and the 
recommendations have not been realistic.
The revised Turkish legislation by 29.12.2015
In accordance with the EU directive mentioned above [27], 
the Turkish legislation has newly been revised as following 
[29]: a) Subjects with severe OSA (AHI>30/h), and subjects 
with moderate OSA (AHI 15-30/h) with documented 
daytime sleepiness should not get driving license unless this 
condition is treated; b) The efficient treatment should be 
documented by a committee of 3 medical doctors, of whom 
one ENT-specialist, and at  least one sleep-certified medical 
doctor (pulmonologist, psychiatrist, neurologist, or ENT-
specialist); following issues should be stated in the report: 
the severity of OSA, response to treatment, compliance 
with positive airway pressure (PAP) device, and if a 
commercial driving-license can be given, and if the person 
can drive ambulance, or official or commercial vehicle; c) 
The applicants with BMI>33 kg/m2 should undergo full-
night PSG regardless of symptoms; d) The applicants with 
witnessed apneas and daytime sleepiness should undergo 
full-night PSG regardless of BMI.
Controversies
The increasing awareness about OSA and its consequences 
on driving is an important step towards increased safety 
on the road. However, there are several problems with the 
current, revised legislation in Turkey:
• The practical application of the directive is demanded 
from the government, and there is yet no standardized 
approach to implementation of the EU directive 
through the national legislation in the current form. 
• Patients with diagnosed OSA represent only a 
very small proportion of a large population with 
unrecognized and untreated OSA, and the new 
requirements established by the government would 
considerably increase the number of requests for 
specialist evaluation, and lengthen waiting lists for 
PSG. 
• Screening for OSA by using a full-night PSG on a 
large scale is not feasible. As the legislation from 
2006 has not seemed to work in practice, there is 
a great risk that the situation will be the same even 
after the current revision, if no concrete, practical 
steps are taken. 
• Although OSA increases the risk of traffic accidents, 
the disorder is associated with EDS in only one 
fifth of the patients according to the population 
studies. The majority of evidence supports the view 
that driving risk in OSA is more closely related to 
the degree of daytime sleepiness than the objective 
severity of OSA in terms of AHI.
• OSA, compared to no-OSA, is associated with a two- 
to three times increased overall risk for MVAs, but 
prediction of risk in an individual is too vague. 
• In literature, there is no compelling evidence to 
restrict driving privileges in patients with OSA, 
if there has not been a motor vehicle crash or an 
equivalent event.
• Other factors than OSA per se, can contribute to 
sleepiness in some individuals with OSA, including 
inadequate sleep time, time of day (early morning 
and afternoon), shift work, sedative medications, 
poor sleep hygiene, other sleep disorders, and 
alcohol intake; and all these additional factors may 
be particularly important in commercial drivers. 
• Subjective EDS in OSA patients is usually assessed 
by questionnaires, which are subjective, and open 
for bias by a driver who seeks to underestimate 
OSA severity, whereas objective evaluation such 
as Multiple Sleep Latency Test or Maintenance of 
Wakefulness Test is expensive, time consuming, and 
not well suited to be performed on a large scale. 
• There is no real consensus regarding which ESS score 
level should be chosen as cut-off for EDS, adapted to 
Turkish population, in the context of driving risk. 
• Patient involvement is particularly important in order 
to minimize the risk of encouraging OSA patients 
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to avoid seeking medical attention and treatment 
because of the understandable concern that such a 
diagnosis would compromise their ability to continue 
driving. This risk is particularly important for 
commercial drivers who depend on a valid driving 
license for their living.
• In literature, there is no evidence that high BMI is 
associated with increased risk for MVAs, except its 
indirect contribution (risk for OSA); and the current 
BMI cut-off level 33 (instead of the previous 25 kg/
m2) for PSG indication is arbitrary, and cannot be 
justified.
How to define a high-risk driver?
Though there is no consensus regarding the definition of  “a 
high-risk driver”, the report from the American Thoracic 
Society (ATS) suggests that a high-risk driver is the one 
who has moderate to severe daytime sleepiness, and a recent 
unintended motor vehicle crash or a near-miss attributable to 
sleepiness, fatigue, or inattention [15]. 
Future perspectives 
According to the ATS recommendations [15], all patients 
being initially evaluated for suspected or confirmed OSA 
should be asked about daytime sleepiness (i.e., falling asleep 
unintentionally and inappropriately during daily activities) as 
well as recent unintended MVAs or near-misses attributable 
to sleepiness, fatigue, or inattention. Patients with these 
characteristics are deemed high-risk drivers and should be 
immediately warned about the potential risk of driving until 
effective therapy is instituted. It is also recommended that 
clinicians should routinely inquire about additional causes 
of sleepiness (e.g., sleep restriction, alcohol, or sedating 
medications), comorbid neurocognitive impairments (e.g., 
depression or neurologic disorders), and diminished physical 
skills as part of the assessment of driving risk. Such factors 
may additively contribute to crashes due to falling asleep 
and affect the efficacy of OSA treatment.
In clinical practice, information that should be routinely 
elicited during an initial visit for patients with suspected 
or confirmed OSA should include the clinical severity of 
the OSA, driving risk, and therapies that the patient has 
received, including behavioral interventions. At subsequent 
visits, adherence and response to therapy should be assessed, 
and the drowsy driving risk should be reassessed if it was 
initially increased. For patients who have suspected or 
confirmed OSA, it’s also important to educate patients and 
their families about drowsy driving and other risks of EDS 
as well as behavioral methods that reduce those risks [15].
For patients in whom there is a high clinical suspicion 
of OSA and who have been deemed high-risk drivers, a full-
night PSG should be performed and, if indicated, treatment 
initiated as soon as possible. However, due to the limitation of 
sleep centers with PSGs and waiting lists, at-home portable 
monitoring is a reasonable alternative to PSG for subjects 
with high clinical suspicion of OSA. The portable devices 
are widely used globally, and are recommended according 
to a final consensus report by the ATS, the American 
Academy of Sleep Medicine, the American College of Chest 
Physicians, and the European Respiratory Society [31]. This 
alternative approach should be considered even in Turkey 
by the national Social Security Institution. A Turkish study 
by Firat and colleagues [32] suggesting that portable sleep 
monitoring is reliable in detecting OSA with AHI>15/h in 
highway bus drivers is important in this context.  
Given the controversies regarding the relationship 
between OSA severity and MVA risk in clinical cohorts 
versus the lack of an association between AHI and 
MVA risk in commercial drivers [30, 33], there is also 
a need for development of screening tools for objective 
evaluation of EDS in such individuals. The Oxford Sleep 
Resistance  (OSLER) Test [34] as well as a recently 
developed neurocognitive test, Gothenburg Sleep Resistant 
(GOSLING) Test seem to be less time-consuming and 
reliable tools to detect attention deficits in OSA patients 
with high MVA risk [35]. 
Conclusions
Sleepiness is an important contributing factor to traffic 
accidents, and the most common medical disorder causing 
sleepiness is OSA. Available data suggest that efficient 
treatment of OSA may reduce risk for MVA-related deaths 
and injuries. The Turkish legislation has recently been revised 
for regulation of driving license issues for individuals with 
OSA. There are still many controversies and difficulties in 
implementation of these rules in practice. A full-night PSG 
is recommended and treatment should be initiated as soon 
as possible when the OSA diagnosis is confirmed. Portable 
cardiorespiratory sleep monitoring is a reasonable alternative 
to PSG for appropriately selected patients with high clinical 
suspicion for OSA, rather than no-PSG, and no treatment. 
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Additional attempts for development of national guidelines 
for determining the driving risk as well as development of 
new screening tools for objective evaluation of sleepiness in 
drivers with suspected or confirmed OSA are urging.
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